SequelSEC

Immunocore Holdings plc IMCR

Biological Products, (No Diagnostic Substances) · CIK 0001671927 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$115.93M
Fiscal year ended 2026-06-30
Operating income
-$3.00M
Fiscal year ended 2026-06-30
Free cash flow
$15.14M
Fiscal year ended 2026-06-30

Immunocore Holdings plc (IMCR) reported revenue of $115.93M and net income of -$808.00K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Immunocore Holdings plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Immunocore Holdings plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$115.93M$106.68M$104.48M$103.69M$97.96M$93.88M$84.05M$80.25M$75.40M$70.50M
Cost of revenue$1.09M$434.00K$2.70M$513.00K$1.04M$831.00K$330.00K$448.00K$1.71M$246.00K
Gross profit$114.84M$106.24M$101.78M$103.18M$96.92M$93.05M$83.72M$79.80M$73.69M$70.26M
Operating income-$3.00M$7.28M-$19.69M-$7.17M-$14.88M-$3.62M-$19.45M-$8.50M-$16.02M-$26.49M
Net income-$808.00K$12.97M-$30.06M-$177.00K-$10.30M$5.02M-$23.77M$8.74M-$11.62M-$24.44M
Research & development$73.94M$61.11M$78.82M$70.57M$69.01M$56.47M$60.85M$52.77M$51.07M$57.46M
Weighted-average diluted sharesshares 50.97Mshares 52.93MUnavailableshares 50.40Mshares 50.29Mshares 51.95MUnavailableshares 52.81Mshares 50.01Mshares 49.88M
Pretax income-$514.00K$13.27M-$15.79M$304.00K-$9.69M$6.08M-$24.82M$6.09M-$10.13M-$24.08M
Income tax expense$294.00K$301.00K$14.27M$481.00K$606.00K$1.06M-$1.05M-$2.64M$1.49M$357.00K
Diluted EPS$-0.02$0.25Unavailable$0.00$-0.20$0.10Unavailable$0.17$-0.23$-0.49
Selling, general & administrative$43.89M$37.85M$42.64M$39.78M$42.79M$40.20M$42.32M$35.53M$38.64M$39.29M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Immunocore Holdings plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$484.92M$452.68M$467.71M$498.41M$487.93M$476.84M$455.73M$537.77M$504.98M$832.82M
Total assets$1.12B$1.07B$1.07B$1.10B$1.08B$1.03B$1.01B$1.08B$1.02B$993.99M
Current assets$1.05B$1.00B$996.74M$1.02B$1.00B$948.62M$929.86M$1.01B$956.86M$926.04M
Total liabilities$699.62M$678.42M$686.24M$705.94M$693.91M$649.53M$648.79M$706.81M$664.23M$634.45M
Current liabilities$235.20M$240.11M$246.70M$170.35M$170.08M$149.16M$212.18M$266.25M$185.10M$155.29M
Total equity incl. NCI$419.80M$393.67M$381.03M$396.56M$388.48M$378.48M$360.72M$377.83M$359.14M$359.53M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$7.79M$8.25M$6.74M$5.66M$5.46M$6.80M$5.45M$4.52M$3.46M$4.17M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$63.01M$63.66M$60.24M$57.75M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$438.70M$452.50M$452.50M
Accounts payable$26.32M$30.16M$24.36M$22.96M$23.86M$29.10M$25.10M$19.72M$19.95M$15.50M

Cash flow

Immunocore Holdings plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$15.93M-$13.78M-$32.66M-$4.46M$25.96M$435.00K-$13.95M$21.13M$23.47M-$4.59M
Capital expenditures$786.00K$1.78M$2.88M$748.00K$414.00K$298.00K$3.58M$828.00K$331.00K$430.00K
Investing cash flow-$786.00K$4.22M-$880.00K$5.25M-$30.41M$9.70M-$3.54M-$828.00K-$350.33M-$430.00K
Financing cash flow$16.48M$656.00K$4.28M$1.87M$3.67M$2.55M-$51.51M$198.00K-$818.00K$396.01M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$9.40M$6.30M$8.34M$9.84M$10.03M$9.49M$8.67M$6.56M$10.00M$8.96M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Immunocore Holdings plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$15.14M-$15.56M-$35.54M-$5.20M$25.55M$137.00K-$17.54M$20.30M$23.14M-$5.02M
Gross margin99.1%99.6%97.4%99.5%98.9%99.1%99.6%99.4%97.7%99.7%
Operating margin-2.6%6.8%-18.8%-6.9%-15.2%-3.9%-23.1%-10.6%-21.2%-37.6%
FCF margin13.1%-14.6%-34.0%-5.0%26.1%0.1%-20.9%25.3%30.7%-7.1%
SBC / revenue8.1%5.9%8.0%9.5%10.2%10.1%10.3%8.2%13.3%12.7%
Current ratio4.47x4.18x4.04x6.00x5.89x6.36x4.38x3.78x5.17x5.96x
Revenue YoY growth18.3%13.6%24.3%29.2%29.9%33.2%19.8%23.7%26.2%29.0%
Net margin-0.7%Unavailable-28.8%-0.2%-10.5%Unavailable-28.3%10.9%UnavailableUnavailable
R&D / revenue63.8%57.3%75.4%68.1%70.4%60.1%72.4%65.8%67.7%81.5%
CapEx / revenue0.7%1.7%2.8%0.7%0.4%0.3%4.3%1.0%0.4%0.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable2.3%Unavailable158.2%Unavailable17.4%Unavailable-43.4%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.